Berkeley Heights, NJ, December 14, 2001
- Genta Incorporated (Nasdaq: GNTA) today announced the appointment
of Patrick J. Zenner to the Companys Board of Directors. Mr. Zenner
is the immediate past President and Chief Executive Officer of
Hoffman-La Roche Inc., North America, which is based in Nutley,
N.J. Roche ranks among the worlds leaders in pharmaceuticals and
diagnostics. Mr. Zenner replaces Mr. Donald Drapkin and Dr. Ralph
Snyderman who are retiring from the Board.
Mr. Zenner is a 31-year veteran of the pharmaceutical industry
and spent his entire career at Hoffmann-La Roche. During his first
12 years, he held positions of increasing responsibility in sales,
marketing, health care economics, public policy and governmental
affairs. In 1982, he became Vice-President and General Manager of
Roche Laboratories, and subsequently Director and Head of Global
Pharma Marketing, Project Development and Regulation in Basel,
Switzerland. In 1988, he became Senior Vice President,
Pharmaceuticals Division and a member of the Board of Directors.
From 1993 until his retirement in 2001, he served as President and
CEO of Hoffmann-La Roche, Inc., North America. Mr. Zenner currently
serves on the Boards of Geron, Inc., Praecis Pharmaceuticals, Inc.
and Dendrite International, Inc. He has also served as a member of
the Board and the Executive Committee of both the Pharmaceutical
Research and Manufacturers Association (PhRMA) and the
Biotechnology Industry Organization (BIO).
"Pat brings a wealth of timely expertise to the Board of Genta,"
said Dr. Raymond P. Warrell, Jr., Gentas Chairman and CEO. "His
experience in general management at one of the worlds largest
pharmaceutical organizations will be enormously useful as our
Company begins its transition to a pharmaceutical marketing model
next year. His personal contacts with global pharma companies, and
his perspectives on the structuring of mutually rewarding
co-marketing and co-development relationships, will also be
especially valuable."
"Genta has one of the most exciting new portfolios in
biotechnology," said Mr. Zenner. "Having known several of Gentas
senior managers for a number of years, I am delighted to assist the
Company in achieving its objectives."
